R. Davis

Anti-PD-L1 Efficacy Can Be Enhanced by Inhibition of Myeloid-Derived Suppressor Cells with a Selective Inhibitor of PI3Kδ/γ.

C. Van Waes, Zhong Chen, J. Friedman, 2017, Cancer research.

Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer.

C. Van Waes, C. Allen, R. Davis, 2016, Oral oncology.

Costimulatory and coinhibitory immune checkpoint receptors in head and neck cancer: unleashing immune responses through therapeutic combinations

R. Ferris, N. Schmitt, R. Davis, 2016, Cancers of the Head & Neck.

Cisplatin Alters Antitumor Immunity and Synergizes with PD-1/PD-L1 Inhibition in Head and Neck Squamous Cell Carcinoma

C. Van Waes, C. Allen, E. Moore, 2017, Cancer Immunology Research.

Resistance to CTLA-4 checkpoint inhibition reversed through selective elimination of granulocytic myeloid cells

C. Van Waes, Zhong Chen, J. Friedman, 2017, Oncotarget.

Established T Cell–Inflamed Tumors Rejected after Adaptive Resistance Was Reversed by Combination STING Activation and PD-1 Pathway Blockade

C. Van Waes, C. Allen, E. Moore, 2016, Cancer Immunology Research.

Avoiding phagocytosis-related artifact in myeloid derived suppressor cell T-lymphocyte suppression assays.

C. Allen, Christopher Silvin, R. Davis, 2017, Journal of immunological methods.